Gary Whale
Vermogen: 199 258 $ op 31-05-2026
Vermogen: 199 258 $ op 31-05-2026
Gary Whale is currently Chief Technology Officer at Zura Bio Ltd. since 2023.
Formerly, Dr. Whale was Vice President & Global Head-Technical Operations at Recordati UK Ltd. from 2020 to 2022 and Chief Operating Officer at VHsquared Ltd. from 2018 to 2020.
Education includes undergraduate and graduate degrees from the University of London and a doctorate from The Robert Gordon University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-04-2026 | 46.339 ( 0,05% ) | 199 258 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ZURA BIO LIMITED | Hoofd Techniek/Wetenschap/O&O | 01-03-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services Supplies medicines and medical devices | Hoofd Techniek/Wetenschap/O&O | 01-01-2022 |
VHsquared Ltd.
VHsquared Ltd. BiotechnologyHealth Technology Develops antibody domain products against gastro intestinal infectious and immune mediated diseases | Operationeel Directeur | 01-04-2020 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Robert Gordon University
The Robert Gordon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
VHsquared Ltd.
VHsquared Ltd. BiotechnologyHealth Technology Develops antibody domain products against gastro intestinal infectious and immune mediated diseases | Health Technology |
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services Supplies medicines and medical devices | Distribution Services |
Zura Bio Ltd.
Zura Bio Ltd. BiotechnologyHealth Technology Operates as a multi-asset clinical-stage biotechnology company that focuses on develops novel medicines for immune and inflammatory disorders | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau